LOG IN/REGISTER >
FORWARD TO A COLLEAGUE >
INDICATION/SAFETY INFORMATION >

Activase (Alteplase) for the treatment of acute ischemic stroke

Educational video

This educational video contains useful information on identifying acute ischemic stroke, determining patient eligibility, dosing and administration, safety, and the positive clinical benefit of Activase (t-PA).

WATCH ENTIRE VIDEO
ORDER VIDEO

OR

Select a chapter from below

Introduction
Provides information on stroke statistics and prevalence as well as an inspiring stroke survivor story.
Stroke is an emergency
Highlights the key steps of prehospital stroke management and the importance of a rapid response.
The pathophysiology and treatment of stroke
Shows the pathophysiology of acute ischemic stroke and the benefit of early reperfusion with fibrinolysis.
The golden hour
Outlines the key steps in assessing, diagnosing, and treating an acute ischemic stroke once the patient presents in the ED.
Reconstituting, dosing, and administering Activase (t-PA)
Walks you through the appropriate reconstitution, dosing, and administration of Activase (t-PA) for eligible stroke patients.
Activase (t-PA) makes a positive clinical difference
Provides clinical data, supporting the safety and efficacy of Activase (t-PA) use in eligible patients.
Indication and Important Safety Information for Activase (t-PA)
Activase (t-PA) indication and safety information.

Assess your understanding with the video In-service Knowledge Check

DOWNLOAD

FAQ brochure

  • Helpful and concise in PDF format, this brochure provides answers to questions about Activase (t-PA)
DOWNLOAD OR ORDER

Indication
Activase (Alteplase) is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see CONTRAINDICATIONS).

Safety Information
Activase therapy in patients with AIS is contraindicated in certain situations (eg, suspicion of subarachnoid hemorrhage on pretreatment evaluation, recent (within 3 months) intracranial or intraspinal surgery, history of intracranial hemorrhage, uncontrolled hypertension at time of treatment, active internal bleeding, known bleeding diathesis (eg, current use of oral anticoagulants, administration of heparin within 48 hours of onset of stroke, platelet count <100,000) (see CONTRAINDICATIONS for full list).

The most common complication during Activase therapy is bleeding. Should serious bleeding in a critical location (intracranial, gastrointestinal, retroperitoneal, pericardial) occur, Activase therapy should be discontinued immediately. Death and permanent disability are not uncommonly reported in patients who have experienced stroke (including intracranial bleeding) and other serious bleeding episodes.

The risks of Activase therapy may be increased and should be weighed against the anticipated benefits in certain conditions. [See WARNINGS in full prescribing information].

  • Patients with severe neurological deficit (eg, NIHSS >22) at presentation. There is an increased risk of intracranial hemorrhage in these patients.
  • Patients with major early infarct signs on a computerized cranial tomography (CT) scan (eg, substantial edema, mass effect, or midline shift).

Treatment of patients with minor neurological deficit or with rapidly improving symptoms is not recommended.

Orolingual angioedema has been observed in postmarketing experience in patients treated with Activase for AIS. Patients should be monitored during and for several hours after infusion for signs of orolingual angioedema.

Please click here for full prescribing information.